Abstract:The most common cause of chronic liver disease throughout the world is nonalcoholic fatty liver disease (NAFLD), which is also characterized by liver fibrosis and inflammation and leads to cirrhosis with progression to hepatic carcinoma in some cases. [ 1 ] NAFLD is a chronic disorder of dysmetabolic syndrome. [ 2 , 3 ] Most cases of NAFLD are characterized by imbalanced glucose levels, obesity, hypertension, hyperlipidemia, and hepatic expression disorders. [ 4 ] This disease affects more than half of the world's population with obesity and diabetes. [ 5 ] The conditions included low-density and high-density lipoprotein, total cholesterol, and hypertriglyceridemia. It has been reported that NAFLD is a presumed cause of chronic liver inflammation in Asian and Western countries. [ 6 ] The prevalence rate of NAFLD is 5% to 30%. However, in the world population, a global survey revealed that Pakistan and India are the countries with the most prevalent type 2 diabetes mellitus (T2DM) and obesity. [ 6 , 7 ] Furthermore, NAFLD incidence is very high among individuals with T2DM, and NAFLD incidence is expected to increase further. T2DM and NAFLD are frequently encountered in general practice. Given the complexity of their management, a multidisciplinary approach is often required, incorporating the expertise of gastroenterologists, diabetologists, and internists. This integrated care model is essential for addressing the multifaceted nature of these conditions. [ 8 ] T2DM and NAFLD are both highly prevalent in primary care, with T2DM affecting over 422 million people globally [ 9 ] and NAFLD affecting 25% to 30% of the general population. [ 9 , 10 ] The conditions are closely linked, especially through insulin resistance, with up to 70% of T2DM patients also having NAFLD. [ 10 ] This coexistence significantly increases the risk of cardiovascular disease and liver complications. [ 11 ] Primary care physicians play a critical role in the early detection and management of both conditions, which requires a multidisciplinary approach involving specialists in diabetology, gastroenterology, and internal medicine. [ 12 ] Effective management focuses on lifestyle changes, pharmacological treatments, and regular monitoring to prevent the progression of these chronic diseases. [ 13 ] Nonalcoholic steatohepatitis (NASH) is a destructive disorder of NAFLD characterized by inflammation, hepatic necrosis, and late fibrosis and may further progress to a crucial form of cirrhosis. [ 14 , 15 ] The early transience rate among NASH patients involves hepatocellular carcinoma and liver cirrhosis, along with extrahepatic manifestations, mostly cardiac disease. [ 3 , 16 , 17 ] The pathogenesis of NAFLD involves multiple factors, including an excessively imbalanced diet and fat-rich food ingestion, along with impaired insulin sensitivity and oxidative stress-induced damage. [ 18 ] However, persistent cellular stress and insulin insensitivity may lead to hepatic steatosis, which causes NAFLD and progression to NASH. [ 19 ] Recent evidence suggested that a sodium-glucose cotransporter 2 (SGLT2) inhibitor improved NAFLD in patients with T2DM. [ 20 ] Ertugliflozin is the newest SGLT2 inhibitor used in patients for the treatment of T2DM. It accelerates urinary glucose excretion, causing a decrease in blood glucose levels, osmotic urination and loss of calories. [ 20 , 21 ] Ertugliflozin improves glucose imbalance and beta cell function, and its effect on insulin sensitivity also decreases body mass. [ 22 ] A decrease in insulin insensitivity caused by canagliflozin treatment is very effective in all patients suffering from NAFLD. [ 23 , 24 ] Recently, established studies have shown that SGLT2 inhibitors considerably decrease body weight and body mass index in human trials. [ 20 </sup -Abstract Truncated-

Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Effect of Empagliflozin and Pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes

Effects of empagliflozin on liver fat in metabolic-dysfunction associated steatotic liver disease patients without diabetes mellitus: A randomized, double-blind, placebo-controlled trial

Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial)

Effects of dapagliflozin on liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled trial

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis

Empagliflozin Treatment Attenuates Hepatic Steatosis by Promoting White Adipose Expansion in Obese TallyHo Mice

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease

Empagliflozin improves left ventricular ejection fraction and end systolic volume in patients with type 2 diabetes mellitus and coronary artery disease: a post-hoc analysis of EMPA-CARD trial

Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials

Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial

SGLT2 inhibition improves endothelium‐independent vasodilatory function in type 2 diabetes: A double‐blind, randomized, placebo‐controlled crossover trial

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice

Effect of empagliflozin on left ventricular volumes in type 2 diabetes or prediabetes heart failure patients with reduced ejection fraction

The effect of ertugliflozin in patients with nonalcoholic fatty liver disease associated with type 2 diabetes mellitus: A randomized controlled trial

Empagliflozin Monotherapy with Sitagliptin As an Active Comparator in Patients with Type 2 Diabetes: a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial